Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Study Shows Sharp Decline in Cancer Screenings During First COVID-19 Surge

January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses, researchers at Dana-Farber/Brigham and...
Benefits Manager Policy Disrupts Patient-physician Decision Making for Breast and Prostate Cancer Radiation Treatments

October 2, 2020 — Radiation oncologists expressed serious concerns about a new private insurance coverage policy that could undermine patient-centered care for two of the most common cancers in the United States.
First U.S. Study Shows Promising Outcomes for High-intensity Focused Ultrasound for Prostate Cancer

September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the high-intensity focused ultrasound (HIFU) technology has gained...
CDC Reports Cancer Death Rates Continue to Decline

March 16, 2020 — The Annual Report to the Nation on the Status of Cancer finds that cancer death rates continued to decline from 2001 to 2017 in the United States for all cancer sites combined.
VIDEO: Use of Hydrogel to Reduce Rectal Toxicity for Prostate Radiotherapy

Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the outcomes of a trial investigating the use of a hydrogel spacer to hold the rectum away from the prostate during radiation therapy treatments.

A new study led by Ivan Martinez—associate professor in the WVU School of Medicine and Cancer Institute—found a link between a family of RNAs, the Y chromosome, and radiation sensitivity in male lung-cancer patients

News | Radiation Therapy | March 23, 2021

Loss of Y chromosome, RNA Tied to Radiation Resistance in Male Lung-cancer Patients

March 23, 2021 — The science behind the COVID-19 vaccine has the potential to do more than prevent cases of COVID-19...

A national screening program targeted at those men who are genetically pre-disposed to prostate cancer, and involving a blood test and magnetic resonance imaging (MRI) scan before an invasive biopsy, could prevent one in six prostate cancer deaths and significantly reduce over-diagnosis, finds a new study led by UCL researchers.

News | Prostate Cancer | March 15, 2021

Targeted Screening for Prostate Cancer Could Prevent One in Six Deaths

March 15, 2021 — A national screening program targeted at those men who are genetically pre-disposed to prostate cancer...

Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.

Feature | Treatment Planning | March 05, 2021 | By Melinda Taschetta-Millane

Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and...

Immunotherapy-based precision medicine clinical trials being developed

News | Prostate Cancer | February 16, 2021

Why Black Men's Prostate Cancer May be More Responsive to Immunotherapy

February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from...

The Milton and Caroll Petrie Department of Urology at Mount Sinai has received a $3.8 million donation from philanthropist Robert F. Smith to launch the Robert F. Smith Mobile MRI Unit in partnership with the Mount Sinai Health System to support prostate health in the Black community.

News | Prostate Cancer | February 12, 2021

Mount Sinai Receives $3.8 Million Gift to Launch Mobile MRI Unit to Support Prostate Health in the Black Community

February 12, 2021 — The Milton and Caroll Petrie Department of Urology at Mount Sinai has received a $3.8 million...

Phase III clinical trial of men with a clinical suspicion of prostate cancer finds MRI with targeted biopsies to be more accurate at diagnosis and less intrusive than current standard

News | Magnetic Resonance Imaging (MRI) | February 08, 2021

Using MRI for Prostate Cancer Diagnosis Equals or Beats Current Standard

February 8, 2021 — The results of a Phase III randomized clinical trial have shown that when it comes to detecting...

News | Prostate Cancer | February 05, 2021

Ultrasound Technique Treats Prostate Cancer with Minimal Side Effects

February 5, 2021 — A technique that delivers high-intensity focused ultrasound to targeted tissue under MRI guidance...

An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost, as shown by a large-scale study initiated by UMC Utrecht in collaboration with the Netherlands Cancer Institute, UZ Leuven and Radboudumc.

News | Prostate Cancer | January 25, 2021

Radiation Boost Lowers Risk of Prostate Cancer Recurrence

January 25, 2021 — An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects...

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.

Detecting Prostate Cancer With Advanced Micro-ultrasound

Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next...

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

News | Coronavirus (COVID-19) | January 15, 2021

Study Shows Sharp Decline in Cancer Screenings During First COVID-19 Surge

January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses,...

The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

News | Prostate Cancer | January 13, 2021

US Prostate Cancer Nuclear Medicine Diagnostics Market Outlook

January 13, 2021 — The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast...

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021

MRI Frequently Underestimates Tumor Size in Prostate Cancer

January 11, 2021 — A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic...

For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

News | Prostate Cancer | December 02, 2020

Radiation Therapy Has the Greatest Impact on Patient Finances

December 2, 2020 — For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "...

Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their manufacturing partner Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence.

News | PET Imaging | November 25, 2020

Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent in Collaboration with Nucleis Radiopharmaceuticals

November 25, 2020 — Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their...

MIM Software Inc. announced a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in support of its Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) program.

News | Prostate Cancer | November 19, 2020

MIM Software Inc. Announces Collaboration with Peter MacCallum Cancer Centre to Improve Patient Management

November 19, 2020 — MIM Software Inc. announced a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in...

During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

News | Prostate Cancer | November 18, 2020

Men with Negative Biopsies During Active Surveillance Have Good Outcomes

November 18, 2020 — Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden...

Penn study supports the use of more testicular shielding for men and children during diagnostics

News | Radiology Imaging | November 16, 2020

Diagnostic Imaging May Increase Risk of Testicular Cancer

November 16, 2020 — Early and repeated exposures to diagnostic imaging, such as X-rays and computed tomography (CT)...

Minimizing delays to treatment could improve cancer survival rates, say researchers

News | Radiation Oncology | November 10, 2020

Every Month Delayed in Cancer Treatment Can Raise Risk of Death by Around 10%

November 10, 2020 — People whose treatment for cancer is delayed by even one month have in many cases a 6 to 13% higher...

In this retrospective cohort study of men with low-risk prostate cancer followed up for a median of 7.6 years, African American men, compared with non-Hispanic White men, had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment, but not metastasis or prostate cancer–specific mortality

News | Prostate Cancer | November 04, 2020

Active Surveillance Safe for African Americans with Low-risk Prostate Cancer

November 4, 2020 — Previous studies have shown that African American men are 2.4 times as likely to die from prostate...

Metastasis-free survival is a strong surrogate endpoint for overall survival over biochemical failure for men receiving salvage radiotherapy for recurrent prostate cancer

News | Prostate Cancer | November 02, 2020

MFS Is a Strong Surrogate Endpoint for OS for Men Receiving Salvage RT

November 2, 2020 — An analysis of the phase III NRG Oncology clinical trial RTOG 9601 on men receiving salvage...

1
2
3
4
5
6
7
8
9
…
next ›